Voyager Therapeutics, Inc. filed an Amendment No. 1 to its current report on November 18, 2026, to correct an inadvertent technical error in the original EDGAR submission header that had referenced the incorrect form item number.
Key Highlights
- Purpose of amendment: The filing was submitted solely to correct an EDGAR submission header that referenced Item 2.01 instead of the correct Items 2.02 and 9.01.
- Original filing date: The original report was filed with the SEC on November 5, 2026, announcing third quarter 2026 financial results and corporate updates.
- No content changes: According to the filing, there are no changes to the original filing itself, which referenced the correct item numbers in its body.
- Exhibit included: A press release dated November 5, 2026, entitled "Voyager Reports Third Quarter 2026 Financial and Operating Results," is furnished as Exhibit 99.1.
- Signed by: Alfred Sandrock, Chief Executive Officer and Director, signed the amendment on November 18, 2026.
Voyager Therapeutics Files Technical Correction to Its Third Quarter 2026 Current Report
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a gene therapy company incorporated in Delaware and headquartered at 75 Hayden Avenue, Lexington, Massachusetts, filed this Amendment No. 1 to address what the company described as "an inadvertent technical error in the submission of the Original Filing through EDGAR which referenced the incorrect Form 8-K Item Number (Item 2.01) in the EDGAR submission header." The amendment corrects the header to reference Items 2.02 and 9.01, which cover results of operations and financial condition, and financial statements and exhibits, respectively.
The filing states that "there are no changes to the Original Filing itself (which referenced the correct Item numbers)" and that the amendment "continues to speak as of the date of the Original Filing and does not reflect events occurring after the date of the Original Filing or modify or update the disclosures therein in any way." The underlying disclosure, a press release reporting the company's third quarter 2026 financial and operating results, remains furnished as Exhibit 99.1 and is incorporated by reference into the amended report.
As noted in the filing, the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not subject to the liabilities of that section unless expressly incorporated by reference in another filing.
What Was Disclosed
Voyager Therapeutics amended its November 5, 2026 current report to fix an EDGAR submission header error that cited the wrong item number. No substantive disclosures were changed, and the underlying third quarter 2026 results press release remained unchanged as Exhibit 99.1.




Please wait processing your request...